Clinical Trial Update: Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety of autologous dendritic cell therapy aimed at suppressing Type 1 diabetes mellitus and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Autologous dendritic cell therapy (dendritic cells (autologous))

Snippet

Sponsor: University of Pittsburgh | Conditions: Type 1 Diabetes | Phase 1 | Status: COMPLETED